Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- CHF | -.--% | -.--% | -100.00% |
10/06 | European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading | MT |
05/06 | UBS Upgrades Smith & Nephew to Buy from Neutral, Raises PT | MT |
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-100.00% | 11.4B | - | ||
+15.40% | 133B | A- | ||
-7.39% | 8.3B | C | ||
+42.58% | 5.69B | B+ | ||
-19.08% | 4.78B | C | ||
+7.67% | 3.42B | C- | ||
-20.08% | 2.48B | B- | ||
-14.06% | 2.03B | - | - | |
-30.52% | 1.59B | C- | ||
-12.86% | 1.16B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SN. Stock
- SN. Stock
- Ratings Smith & Nephew plc